leadf
logo-loader
viewVolitionRx

VolitionRx to present coronavirus triage test advancements at Proactive's One2One Conference

VolitionRx Limited (NYSEAMERICAN:VNRX) Head of Investor Relations and US CFO Scott Powell tells Proactive the group will present its recent coronavirus triage test advancements at Proactive's One2One Conference today at 1pm EST.

Powell says the biotech has revealed promising results from two proof-of-concept clinical studies of its coronavirus triage test using its flagship Nu.Q test (normally used to detect cancer biomarkers) to predict the likelihood that a positive individual will develop complications and severe disease.

Quick facts: VolitionRx

Price: 4.01 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $193.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

VolitionRx Limited ends its 3Q with $21M in the bank, looks forward to...

VolitionRx Limited (NYSE AMERICAN:VNRX) CEO Cameron Reynolds tells Proactive the group finished its third quarter with around $21M in the bank compared with $17M at the end of 2019. Reynolds also discussed upcoming milestones including the preparing to launch its new product, Nu.Q™ Vet Cancer...

on 11/13/2020

2 min read